Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer

Zhong-He Ji; Kai-Wen Peng; Yan Li

doi:10.21037/tgh.2016.08.03

Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer

Transl Gastroenterol Hepatol. 2016 Sep 19:1:69. doi: 10.21037/tgh.2016.08.03. eCollection 2016.

Authors

Zhong-He Ji¹, Kai-Wen Peng¹, Yan Li¹

Affiliation

¹ Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital affiliated to the Capital Medical University, Beijing 100038, China.

Abstract

Peritoneal carcinomatosis (PC) is one of the most common causes of death in gastric cancer patients. Intraperitoneal free cancer cells (IFCCs) play a very important role in forming PC, but the administration of intraperitoneal chemotherapy (IPC) and/or hyperthermic intraperitoneal chemotherapy (HIPEC) could be an effective treatment for IFCCs. This review focuses on the origin of IFCCs, the mechanism of PC formatting, the rationale of IPC/HIPEC, and the current clinical trials on IPC/HIPEC to treat advanced gastric cancer patients.

Keywords: Intraperitoneal free cancer cells (IFCCs); gastric cancer (GC); hyperthermic intraperitoneal chemotherapy (HIPEC); intraperitoneal chemotherapy (IPC); peritoneal carcinomatosis (PC).

Publication types

Review